Drug Trial Radar · NCT04006210
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
381
Actual
Start
Sep 30, 2019
Primary completion
Nov 1, 2022
Study completion Feb 2027
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.
Conditions
- Parkinson's Disease
Interventions
ND0612 Solution for SC infusionCombination product
Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
Placebo for SC infusionCombination product
Placebo solution administered SC via infusion pump
Oral IR-LD/CDDrug
Encapsulated LD/CD 100mg/25mg
Placebo for Oral IR-LD/CDDrug
Encapsulated Placebo for LD/CD 100mg/25mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in daily ON time without troublesome dyskinesiaTime frame: Baseline to the end of DBDD Maintenance Period (12 weeks)
Locations
103 sites in 16 countries. Site status is shown where the registry gives one.
Xenoscience
Phoenix, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Cedar- Sinai Medical Center Department of Neurology
Los Angeles, California
SC3 Research - Reseda
Reseda, California
University of California San Francisco
San Francisco, California
Rocky Mountain Movement Disorders Center
Englewood, Colorado
Hartford Healthcare Chase Family Movement Disorders Center
Vernon, Connecticut
Visionary Investigators Network
Aventura, Florida
Parkinsons Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
University of Florida Norman Fixel Institute for Neurological Diseases
Gainesville, Florida
Neurology Associates PA
Maitland, Florida
USF Parkinson's Disease and Movement Disorders Center
Tampa, Florida
Neurology One
Winter Park, Florida
Emory University - Brain Health Center
Atlanta, Georgia
NeuroStudies
Decatur, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Rush University Medical Center
Chicago, Illinois
Unity Point Health
Des Moines, Iowa
University of Kansas Medical Center
Kansas City, Kansas
University of Kentucky, Neurology and Movement Disorder
Lexington, Kentucky
Oschner Medical Center
New Orleans, Louisiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Michigan State University
East Lansing, Michigan
QUEST Research Institute
Farmington Hills, Michigan
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Weill Cornell Medicine
New York, New York
Mount Sinai Medical center Movement Disorders Center
New York, New York
Duke University
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Abington Neurological Associates LTD.
Willow Grove, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Neurology Consultants of Dallas
Dallas, Texas
University of Vermont Medical Center
Burlington, Vermont
University of Virginia
Charlottesville, Virginia
University of Wisconsin Madison
Madison, Wisconsin
Medical University Innsbruck
Innsbruck, Austria
CHU de Tivoli
La Louvière, Belgium
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.